Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989693 | 0.94 | DRD4 (0.37) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989569 | 0.93 | DRD4 (0.35) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989716 | 0.92 | DRD2 (0.35) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989662 | 0.92 | DRD4 (0.35) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989674 | 0.89 | MEN1 (0.34) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989629 | 0.87 | MEN1 (0.35) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL20001448 | 0.86 | HTR1D (0.31) | DRD4MEN1KMT2AHTR1A | |
| SCHEMBL19989625 | 0.85 | HTR1A (0.37) | DRD4MEN1KMT2AHTR1A | |
| SCHEMBL19989682 | 0.85 | DRD4 (0.34) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL19989606 | 0.84 | DRD2 (0.43) | DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088087-B | Tetrahydropyridine derivatives and their use as antibacterial agents | 东亚ST株式会社 | 2022-08-09 | — | — | CN | disclosed |
| EP-3519387-B1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG A ST CO LTD (KR) | 2021-08-11 | — | — | EP | disclosed |
| EP-3519387-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Dong-A ST Co., Ltd. (KR) | 2019-08-07 | — | — | EP | disclosed |
| US-10160724-B2 | Tetrahydropyridine derivatives and their use as antibacterial agents | DONG-A ST CO., LTD. (KR) | 2018-12-25 | — | — | US | disclosed |
| WO-2018062924-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | GALE, UGDH, PGLS | DRD4 2048/4885DRD2 1345/4885DRD3 1596/4885 |
| US-10160724-B2 | Tetrahydropyridine derivatives and their use as antibacterial agents | GALE, UGDH, PGLS | DRD4 2048/4885DRD2 1345/4885DRD3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.